---
reference_id: "PMID:23083758"
title: "Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs."
authors:
- Poddubnyy D
- van der Heijde D
journal: Rheum Dis Clin North Am
year: '2012'
doi: 10.1016/j.rdc.2012.08.005
content_type: abstract_only
---

# Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs.
**Authors:** Poddubnyy D, van der Heijde D
**Journal:** Rheum Dis Clin North Am (2012)
**DOI:** [10.1016/j.rdc.2012.08.005](https://doi.org/10.1016/j.rdc.2012.08.005)

## Content

1. Rheum Dis Clin North Am. 2012 Aug;38(3):601-11. doi:
10.1016/j.rdc.2012.08.005.  Epub 2012 Sep 15.

Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory 
drugs.

Poddubnyy D(1), van der Heijde D.

Author information:
(1)Rheumatology, Medical Department I, Campus Benjamin Franklin, Charité 
Universitätsmedizin Berlin, Berlin 12203, Germany. denis.poddubnyy@charite.de

Nonsteroidal anti-inflammatory drugs (NSAIDs) are considered a first-line 
therapy in patients with axial spondyloarthritis (axSpA), including ankylosing 
spondylitis. NSAIDs reduce pain and stiffness effectively in most patients, are 
able to reduce systemic and local inflammation, and can inhibit progression of 
structural damage in the spine. However, effective control of symptoms and 
retardation of radiographic progression often require continuous and long-term 
treatment, which raises safety concerns. This article discusses controversies 
related to the current role of NSAIDs in axSpA treatment, risks and benefits of 
this treatment, and current trends for individualized treatment.

Copyright © 2012 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.rdc.2012.08.005
PMID: 23083758 [Indexed for MEDLINE]